Genzyme,
a Sanofi company SNY, announced today
new data from Genzyme's clinical development programs for AUBAGIO®
(teriflunomide) and LEMTRADATM (alemtuzumab) will be
presented at the 28th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France,
October 10-13.
“The data to be presented at ECTRIMS are a reflection not only of the
comprehensive clinical development programs supporting AUBAGIO and
LEMTRADA, but of the unique commitment and substantial progress Genzyme
has made to date in bringing forward differentiated therapies in
multiple sclerosis,” said Genzyme CEO and President, David Meeker.
Once-daily, oral AUBAGIO is
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in